乙型肝炎病毒感染与妊娠肝内胆汁淤积症的相关性研究

目的　探讨无症状乙型肝炎病毒 (HBV)感染是否会影响妊娠肝内胆汁淤积症 (ICP)的发生率、病程及相关并发症。方法　 1997年 1月至 2 0 0 1年 7月对 76 5 1例孕妇进行乙型肝炎 (乙肝 )血清学测定 ,分析比较乙肝血清学HBV表面抗原 (HBsAg)、HBVe抗原 (HBeAg)及HBV核心抗体 (HBcAb)阳性孕妇与阴性孕妇其ICP发生、转归的相关性。结果　在有HBV感染的孕妇中其ICP的发生率明显高于无HBV感染的孕妇 (分别为 9 7%及 4 2 % ,P <0 0 0 1)。有HBV感染的孕妇发生ICP瘙痒症状的时间明显早于无HBV感染的孕妇 ,分别为( 2 8 8± 3 2 )周及 ( 32 1± 2 7)周 ,P <0 0 0 1。有HBV感染的ICP孕妇终止妊娠时间明显早于无HBV感染的ICP孕妇 ,分别为 ( 36 1± 0 9)周及 ( 37 8± 1 6 )周 ,P <0 0 0 1。在ICP组中有无HBV感染其早产发生率差异有非常显著性意义 ,分别为 2 9 5 %及 12 2 % ,P <0 0 0 1。ICP孕妇中有无HBV感染产后 2 4h内阴道出血量差异也有非常显著性意义 ,分别为 ( 335 0± 76 7)mL及 ( 2 78 0± 97 6 )mL ,P<0 0 0 1。结论　感染了HBV的孕妇其ICP的发生率增高 ,应加强对这些孕妇的孕期监护 ,并且积极防治早产及产后出血的发生。     

Hepatitis C virus infection is associated with a higher incidence of cholestasis of pregnancy

To investigate a possible relationship between hepatitis C virus infection and cholestasis of pregnancy, we identified all cases of cholestasis of pregnancy (145/16,271) and hepatitis C virus infection (63/16,27 1) between January 1992 and December 1997. Serologic screening was performed universally. The rate of cholestasis of pregnancy was greater in women whose hepatitis C virus antibodies were positive rather than negative [15.9% (10/63) vs 0.8% (135/16,208),   P < 0.0011  . Among women with cholestasis of pregnancy, mean (standard deviation) gestational age at onset of symptoms and at delivery was significantly lower among women whose hepatitis C virus antibodies were positive compared with negative women: 28.9 (3.2) vs 34.3 (3–5) weeks,   P < 0.001  and 36–3 (0.9) vs 37.0 (1–6) weeks,   P = 0.03  , respectively. These findings suggest that early Occurrence of cholestasis of pregnancy may be an indication for serologic testing for hepatitis C virus.     

Obstetric risks and vertical transmission of hepatitis C virus infection in pregnancy

BACKGROUND: Reports of obstetric complications of mothers infected with hepatitis C virus (HCV) are limited and the risk of mother-to-infant transmission varies widely. We assessed the course of pregnancy in HCV-infected women and the rate of vertical transmission. METHODS: Between October 1992 and December 1996, 3712 pregnant patients of the university hospital Grosshadern Munich, Germany, were screened for anti-HCV and analyzed for HCV-RNA by polymerase chain reaction. Clinical and biochemical parameters were monitored. Children born to HCV-positive women were followed up at 6, 12 and 18 month intervals and screened for anti-HCV and HCV-RNA. RESULTS: Thirteen (42%) of 31 anti-HCV positive patients had a cesarean section which was twice the rate of that in the HCV-negative group (p=0.004). None of the cesarean deliveries was due to complications directly caused by HCV infection. Nine (29%) of 31 anti-HCV positive women had preterm delivery compared to 19% in the anti-HCV negative patients, the difference being statistically not significant. Fetal outcome parameters such as APGAR score, umbilical pH and birth weight of HCV infected pregnancies were not impaired. All 29 babies tested for anti-HCV were seropositive after birth. Between 12 and 18 months of age, 10% of the infants still were anti-HCV positive, whereas only one baby was HCV-RNA positive beyond 12 months yielding a vertical transmission rate of 5% among HCV-RNA positive mothers. CONCLUSION: Anti-HCV positive pregnancies have an increased risk of cesarean delivery, probably due to the high-risk collective of anti-HCV positive mothers. The mother-to-child transmission rate is low and linked to maternal HCV-RNA positivity.     

Hepatitis C virus infection is associated with a higher incidence of cholestasis of pregnancy.

To investigate a possible relationship between hepatitis C virus infection and cholestasis of pregnancy, we identified all cases of cholestasis of pregnancy (145/16,271) and hepatitis C virus infection (63/16,271) between January 1992 and December 1997. Serologic screening was performed universally. The rate of cholestasis of pregnancy was greater in women whose hepatitis C virus antibodies were positive rather than negative [15.9% (10/63) vs 0.8% (135/16,208), P < 0.001]. Among women with cholestasis of pregnancy, mean (standard deviation) gestational age at onset of symptoms and at delivery was significantly lower among women whose hepatitis C virus antibodies were positive compared with negative women: 28.9 (3.2) vs 34.3 (3.5) weeks, P < 0.001 and 36.3 (0.9) vs 37.0 (1.6) weeks, P = 0.03, respectively. These findings suggest that early occurrence of cholestasis of pregnancy may be an indication for serologic testing for hepatitis C virus.     

Seroprevalence and assessment of risk factors for hepatitis C virus infection in pregnancy

Screening for hepatitis B is routinely performed in most antenatal clinics. Whether the same should occur for hepatitis C needs to be assessed for each population by determining the prevalence of this infection within the community and whether any particular high-risk group can be identified. A series of 2,000 consecutive patients attending for antenatal care at the Mercy Hospital for Women, Melbourne, was tested for evidence of hepatitis C infection. The prevalence of hepatitis C infection in this group was 1.45% (95% confidence interval 0.97-2.1%). Significant independent risk factors were a history of intravenous drug use, blood transfusion and previous pregnancy ending prior to 20 weeks' gestation. Currently no treatment exists for hepatitis C and as there are no effective means of preventing transmission to the baby, routine screening cannot be justified in view of the low prevalence of this infection among antenatal patients. Selective screening of patients with relevant risk factors for hepatitis C should be carried out as the most efficient and cost-effective strategy in pregnancy.     

Hepatitis C virus infection in pregnancy

Objective To evaluate the clinical aspects of hepatitis C virus (HCV) liver disease in anti-HCV + ve mothers, both during pregnancy and six months after delivery, and to assess the outcome of pregnancy.
Setting Obstetric department for high risk pregnancies of the University of Padova, Italy.
Participants Seventeen hundred consecutive pregnant women were studied.
Methods Each woman underwent the following: 1. serological screening for hepatitis surface antigen (HBsAg), antibodies to HCV (anti-HCV), antibodies to human immunodeficiency virus type 1 (HIVI) within the first trimester of pregnancy; and 2. clinico-biochemical assessment in order to ascertain previous or active liver disease and risk factors for viral infections.
Results Twenty-nine (1.7%) of the 1700 women were found anti-HCV positive. Eight of them had an associated positivity for HIV infection. HCV-RNA was positive in 64.2% of anti-HCV positive women. Liver function tests (included transaminases) were within the normal range in 27 mothers (both during and six months after delivery). Only 2/29 women had a slight increase in AST/ALT; liver biopsy in these cases was compatible with mild chronic active hepatitis. In all women the outcome of pregnancy was favourable (12/29 anti-HCV positive mothers underwent caesarean delivery for causes independent from HCV infection).
Conclusions A substantial proportion of anti-HCV positive pregnant mothers, even if asymptomatic, have circulating HCV-RNA. The pregnancy does not induce a deterioration of liver disease, and vice versa, HCV infection does not increase the risk of obstetric complications.     

妊娠合并乙型肝炎病毒感染对妊娠结局的影响

目的：探讨妊娠合并乙肝病毒感染影响妊娠结局的因素。方法：采用回顾性方法分析了1989年1月至1992年12月期间183例妊娠期存在乙肝病毒感染者的妊娠结局。结果：(1)妊娠合并乙肝病毒感染各并发症的发生率：胎膜早破21．31％，早产12．02％，妊高征10．38％，胎儿窘迫12．02％，产后出血3．23％，新生儿窒息10．38％；(2)妊娠合并乙肝病毒感染有肝功能异常组与肝功能正常组相比其早产(28．17％)、妊高征(22．54％)、胎儿窘迫(25．35％)、产后出血(8．45％)发生率均明显增高，新生儿出生体重则明显降低。结论：妊娠合并乙肝病毒感染，易发生胎膜早破、早产、妊高征、胎儿窘迫及产后出血，肝功能异常对这些妊娠并发症的发生有显著影响。应重视该类病例的治疗。     

妊娠合并乙型肝炎病毒感染孕妇胎儿窘迫发病原因分析

目的：探讨妊娠合并乙型肝炎病毒（HBV）感染孕妇胎儿窘迫的病因、预后及治疗方法。方法：对81例妊娠期HBV表面抗原（HBsAg）、HBVe抗原（HBeAg)、HBV核心抗体（HBcAb)和HBV DNA均阳性,肝功能正常的孕妇及其新生儿（研究组）,85例无肝炎病毒感染,肝功能正常的孕妇及新生儿（对照组）的临床资料、血清学检查结果、胎盘病理检查结果和胎儿预后进行分析,并对研究组中76例婴儿在出生后0、1、6月龄时分别注射酵母菌重组乙型肝炎疫苗10μg,24月龄时检测婴儿HBV表面抗体（HBsAb),以评价母婴HBV阻断效果。结果：（1）研究组胎儿窘迫的发生率为38．3％,对照组为16．5％,两组比较差异有显著性（P＜0．05）。（2）HBV感染胎盘可导致绒毛膜血管病。（3胎儿窘迫者,24月龄时母婴阻断率为78．6％,无胎儿窘迫者母婴HBV阻断率为91．7％,两 者比较,差异有显著性（P＜0．05）。结论：妊娠合并HBV感染,可引起胎盘绒毛膜血管病,致使胎盘功能下降,临床表现为胎儿窘迫、进而导致HBV母婴阻断失败。     

Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis

OBJECTIVE: The purpose of this study was to determine whether routine hepatitis C virus screening in pregnancy is cost-effective. STUDY DESIGN: A decision tree with Markov analysis was developed to compare 3 approaches to asymptomatic hepatitis C virus infection in low-risk pregnant women: (1) no hepatitis C virus screening, (2) hepatitis C virus screening and subsequent treatment for progressive disease, and (3) hepatitis C virus screening, subsequent treatment for progressive disease, and elective cesarean delivery to avert perinatal transmission. Lifetime costs and quality-adjusted life years were evaluated for mother and child. RESULTS: In our base case, hepatitis C virus screening and subsequent treatment of progressive disease was dominated (more costly and less effective) by no screening, with an incremental cost of 108 US dollars and a decreased incremental effectiveness of 0.00011 quality-adjusted life years. When compared with no screening, the marginal cost and effectiveness of screening, treatment, and cesarean delivery was 117 US dollars and 0.00010 quality-adjusted life years, respectively, which yields a cost-effectiveness ratio of 1,170,000 US dollars per quality-adjusted life year. CONCLUSION: The screening of asymptomatic pregnant women for hepatitis C virus infection is not cost-effective.     

GB virus C infection in pregnancy: Maternal and perinatal importance of the infection

Objectives

The more effective way of transmission of GB virus C (GBV-C) is parenteral, but sexual and vertical transmission seem to be the main way of spreading. We evaluated the prevalence and the effect of GBV-C infection on pregnant women, vertical transmission and viral effects on the newborn.

Study design

This study has consecutively enrolled 879 pregnant women. All patients had blood sampling to determine GBV-C RNA, serologic tests for chronic viral infections and seric tests of hepatic damage. The newborns from infected mothers had blood sampling to detect the presence of GBV-C at birth, and after 3 and 6 months. Positive babies were checked until 18 months.

Results

36 (4.1%) women resulted GBV-C positive. Among the positive patients none presented complications during pregnancy. Neither embryonic-fetal abnormalities nor relevant differences in fetal birth weight and week of gestation at delivery were found. 20 out of 36 babies had a follow-up. At birth, 13 (65%) babies were positive. 4 out of 9 vaginal deliveries (44%) and 9 out of 11 cesarean sections (82%) resulted positive to GBV-C RNA. The risk of GBV-C vertical transmission was not significantly increased by type of delivery (p = 0.274). At 3 months, 13 babies were GBV-C positive (65%) and 7 were negative (35%). At the end of the follow-up, 9 babies were positive (45%), while 11 were negative (55%).

Conclusion

The percentage of patients positive to GBV-C RNA was comparatively high (4.1%). This prevalence, in a population without particular risk factors, confirms that common ways of transmission, such as the sexual and vertical ones, might have an important role in viral diffusion. Our data suggest that the infection does not influence the course of pregnancy. The rate of transmission found in our study is high. Type of delivery does not seem to be actually involved in vertical transmission and the protective role of cesarean section has not been confirmed.     

Human immunodeficiency virus infection in pregnancy

Many aspects of HIV infection in pregnancy remain unclear. Subsets at increased risk for perinatal transmission, adverse pregnancy outcome, and development of symptomatic HIV infection need to be identified. For instance, relative risks may be quite different in asymptomatic HIV infected patients with T4 lymphocyte counts greater than 200 cells per cubic millimeter compared to those with either symptoms of HIV infection or T4 cell counts less than 200 cells per cubic millimeter. At present, antiviral therapeutic trials do not include pregnant women or neonates less than 3 months of age. In the future, antiviral therapy with agents, such as AZT, may reduce the risk of transplacental and intrapartum HIV transmission. Obstetricians will be involved increasingly in providing care to HIV-infected patients and educating patients in order to prevent HIV infection.     

Human immunodeficiency virus infection in pregnancy

Among an estimated 1 million to 1.5 million Americans infected with HIV, about 10 per cent are women. Moreover, almost 30 per cent of HIV infection among women is acquired through heterosexual activity. Therefore, the average obstetrician/gynecologist is not sheltered from dealing with HIV. This article offers guidelines for caring for HIV-infected pregnant women during antepartum, intepartum, and postpartum phases.